title: Considerations in the pharmacoeconomics of dry eye.
abstract: Dry eye disease diminishes the quality of patients' lives and drives utilization of health care resources. Until recently, all treatments for dry eye have been palliative. A new treatment, cyclosporine A ophthalmic emulsion, addresses the disease's underlying causes. It warrants pharmacoeconomic analysis to determine its place in managed care.
authors.affiliation: Prescription Solution, Cost Mesa, Calif., USA.
authors.forename: Jan D
authors.initials: JD
authors.lastname: Hirsch
mesh_terms: D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D017850:Economics, Pharmaceutical; D004655:Emulsions; D005260:Female; D006801:Humans; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000191:economics / Q000627:therapeutic use; D010166:Palliative Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004655:Emulsions; D009883:Ophthalmic Solutions; D016572:Cyclosporine